Anand Prakash Singh

Employment

Employment history is unavailable.

Education

Education history is unavailable.

Projects & Funding

Projects & funding information is unavailable.

Publications (36)

• Cardiovascular Adverse Event Reporting Patterns for Atenolol, Bisoprolol, and Nebivolol: A Pharmacovigilance Disproportionality Analysis of the FDA Adverse Event Reporting System
  Cardiovascular Medicine 2026 DOI: 10.3390/cardiovascmed29040041
  +Save
• Sotagliflozin Reprograms Hepatic Lipid Metabolism and Attenuates Atherosclerosis Beyond Empagliflozin in CKM Mice
  2026 DOI: 10.64898/2026.09.25.754502
  +Save
• Autotaxin Inhibition Ameliorates HFpEF Phenotype By Reducing LPA-Mediated Systemic Inflammation and Cardiac Remodeling
  2026 DOI: 10.64898/2026.08.26.747366
  +Save
• Abstract Mon130: Pharmacovigilance Analysis of Clozapine-Associated Cardiovascular Adverse Events: A Disproportionality Study Using FAERS
  Circulation Research 2026 DOI: 10.1161/res.139.suppl_1.mon130
  +Save
• Abstract Mon141: Sotagliflozin Reverses Diastolic Dysfunction via Metabolic Reprogramming and Anti-Inflammatory Mechanisms in Experimental HFpEF
  Circulation Research 2026 DOI: 10.1161/res.139.suppl_1.mon141
  +Save
• Abstract Wed006: Resident Macrophages Promote Angiogenic Myocardial Preservation in the Regenerative Mammal Acomys
  Circulation Research 2026 DOI: 10.1161/res.139.suppl_1.wed006
  +Save
• Abstract Wed034: Circulating suPAR Promotes Diastolic Dysfunction in Metabolic HFpEF
  Circulation Research 2026 DOI: 10.1161/res.139.suppl_1.wed034
  +Save
• Soluble Urokinase Plasminogen Activator Receptor Primes Macrophages and Worsens Heart Failure with Preserved Ejection Fraction
  2026 DOI: 10.64898/2026.06.04.730230
  +Save
• Abstract Or117: Dual Inhibition of Sodium-Glucose Cotransporters 1 and 2 Attenuates Atherosclerosis via Metabolic Reprogramming Toward Fatty Acid Oxidation
  Arteriosclerosis, Thrombosis, and Vascular Biology 2026 DOI: 10.1161/atvb.46.suppl_1.or117
  +Save
• Complosome Activation after Myocardial Infarction in a Murine Model of Permanent LAD Ligation
  Stem Cell Reviews and Reports 2026 DOI: 10.1007/s12015-025-11044-x
  +Save
• Pharmacovigilance-Based Safety Profile of Bortezomib: A Disproportionality Analysis Using FAERS Data
  Cardiovascular Medicine 2026 DOI: 10.3390/cardiovascmed29010004
  +Save
• Targeting Metabolic Dysfunction and Inflammation with Sotagliflozin Reverses Diastolic Dysfunction in Experimental HFpEF
  2025 DOI: 10.1101/2025.11.27.691021
  +Save
• Cardiac ageing: from hallmarks to therapeutic opportunities
  Cardiovascular Research 2025 DOI: 10.1093/cvr/cvae124
  +Save
• Ponatinib Drives Cardiotoxicity by S100A8/A9-NLRP3-IL-1β Mediated Inflammation
  Circulation Research 2023 DOI: 10.1161/CIRCRESAHA.122.321504
  +Save
• Fibroblast GSK-3α Promotes Fibrosis via RAF-MEK-ERK Pathway in the Injured Heart
  Circulation Research 2022 DOI: 10.1161/CIRCRESAHA.122.321431
  +Save
• Animal Models of Exercise From Rodents to Pythons
  Circulation Research 2022 DOI: 10.1161/CIRCRESAHA.122.320247
  +Save
• Cardiovascular Complications of Immune Checkpoint Inhibitors
  Immune Cells, Inflammation, and Cardiovascular Diseases 2022
  +Save
• Safety profile of D-penicillamine: a comprehensive pharmacovigilance analysis by FDA adverse event reporting system
  Vijay Kumar, Anand Prakash Singh, Nicholas D. Wheeler +2 more
  Expert Opinion on Drug Safety 2021 DOI: 10.1080/14740338.2021.1956460
  +Save
• Repurposing Nintedanib for pathological cardiac remodeling and dysfunction.
  Pharmacological research 2021 DOI: 10.1016/j.phrs.2021.105605
  +Save
• Proteotoxicity: A Fatal Consequence of Environmental Pollutants-Induced Impairments in Protein Clearance Machinery
  Shweta Devi, Jong-Joo Kim, Anand Prakash Singh +5 more
  Journal of Personalized Medicine 2021 DOI: 10.3390/jpm11020069
  +Save